Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program.
Inversago scientists identified Diabetic Kidney Disease as the most promising indication for a Phase 2 study, given its important unmet medical need. Such a study presents an opportunity to evaluate a comprehensive set of biomarker data in DKD that may also be relevant to a broad landscape of diabetic-related indications, including cardiometabolic and fibrotic complications.
INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversago’s lead program.
Dr. Glenn Crater, CMO at Inversago, stated: “This IND clearance is an important milestone for Inversago and marks the beginning of an important regulatory and clinical process in bringing a new therapeutic approach to patients suffering from Diabetic Kidney Disease.”
“We are excited to report this significant achievement for our first-in-class, peripherally-acting CB1 inverse agonist, which confirms our leadership in this field. We believe that CB1 blockers, such as INV-202, offer opportunities in multiple therapeutic areas,” added François Ravenelle, PhD, Chief Executive Officer of Inversago.
Inversago believes that peripheral CB1 blockade, either alone or in combination with other therapies, represents an opportunity to address the significant unmet medical need of DKD. As obesity, diabetes and their complications continue to affect more people around the world, the need for new therapies will only continue to grow.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including Diabetic Kidney Disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of a peripheral CB1 blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs.
About Diabetic Kidney Disease
Diabetic Kidney Disease (DKD) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease. Like other chronic diseases, it is expected that multiple mechanisms are needed to achieve adequate control of this progressive disease. Inversago believes that peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. For more information, visit inversago.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005424/en/
Contact information
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.
info@inversago.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Collaborates with Mercurial Minds to Enhance Digital Transformation Capabilities1.7.2025 16:30:00 EEST | Press release
Andersen Consulting expands its capabilities in delivering technology-driven solutions with the addition of collaborating firm Mercurial Minds (M.M.), a digital transformation, AI, and IT consulting firm based in Pakistan. Founded in 2013, M.M. provides a suite of services designed to help organizations evolve and scale, including their digital transformation strategy, AI services, IT consulting, and the development of robust mobile and web user experiences. The firm delivers end-to-end solutions—defining data-driven roadmaps, engineering intelligent automation, and delivering secure mobile and web experiences that scale—tailored for businesses seeking to enhance connectivity and unlock real-time insights. M.M. serves a diverse range of industries, with a focus on the financial, telecommunications, and other data-intensive sectors. “This collaboration is a catalyst,” said Nabeel Saiyer, CEO of M.M. “Our goal is to shape sentient systems that continually learn and adapt. Collaborating w
Planet Awarded €240 Million Satellite Services Deal1.7.2025 16:03:00 EEST | Press release
Planet Labs Germany GmbH, a leading provider of daily data and insights about Earth, today announced a multi-year €240 million agreement, funded by the German government, in support of European peace and security. Through the agreement, Planet will provide dedicated capacity and direct downlink services on Pelican satellites over specific European regions. This deal also includes access to PlanetScope and SkySat data, along with AI-enabled solutions for enhanced situational awareness and maritime domain awareness. The contract will provide high-resolution imagery and timely intelligence via dedicated capacity on Pelican satellites, including those being built for our previously announced satellite services agreement. This satellite services ‘dedicated capacity’ model offers a cost-effective and efficient way for customers to gain access to advanced space-based capabilities without the operational complexities of building and maintaining their own satellite infrastructure. “We are incre
Esports World Cup Foundation and Lenovo™ Partner to Power the Next Generation of Esports Champions1.7.2025 16:00:00 EEST | Press release
The Esports World Cup Foundation (EWCF) and Lenovo today announced a partnership to make Lenovo’s Legion brand of gaming devices the Official PC & Gaming Hardware partner of the Esports World Cup 2025 (EWC). Lenovo Legion is the one of the world’s leading gaming ecosystem brands, and will be bring its relentless commitment to innovation and performance to the global stage, empowering EWC athletes to compete at their highest level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626760677/en/ From training rooms to tournament zones, EWC athletes will be equipped with Lenovo Legion Towers, Lenovo Legion laptops, and peripherals – built for elite esports play with advanced thermal systems, high-performance silicon, high refresh-rate displays and low latency keyboards and mice that meet the demands of top-level competition. Key models such as the Legion Tower 7i and Legion Tower 5i will feature across the event’s player infras
Citigroup Announces €1.75 Billion Redemption of 1.250% Fixed Rate/Floating Rate Notes Due 20261.7.2025 15:30:00 EEST | Press release
Citigroup Inc. is announcing the redemption, in whole, constituting €1,750,000,000 of its 1.250% Fixed Rate/Floating Rate Notes due 2026 (the “notes”) (ISIN: XS2167003685). The redemption date for the notes is July 6, 2025 (the “redemption date”). The cash redemption price for the notes payable on the redemption date will equal par plus accrued and unpaid interest, to but excluding, the redemption date and will be paid on July 7, 2025, the next succeeding business day after the redemption date. The redemption announced today is consistent with Citigroup's liability management strategy and reflects its ongoing efforts to enhance the efficiency of its funding and capital structure. Citigroup will continue to consider opportunities to redeem or repurchase securities, based on several factors, including without limitation, the economic value, regulatory changes, potential impact on Citigroup's net interest margin and borrowing costs, the overall remaining tenor of Citigroup's debt portfoli
LevelBlue to Acquire Trustwave, Becoming Largest Pure-Play Managed Security Services Provider1.7.2025 15:00:00 EEST | Press release
LevelBlue, a global leader in cloud-based, AI-driven managed security services (MSS), has signed a definitive agreement to acquire Trustwave, a global provider of cybersecurity and managed detection and response (MDR) services from the MC2 Security Fund (MC2), a private equity fund sponsored by The Chertoff Group, an internationally recognized security and growth advisory firm. This strategic acquisition complements LevelBlue’s recent agreement to acquire Aon’s cybersecurity consulting business, formerly known as Stroz Friedberg, and further strengthens the company’s market leadership, uniting two leading Managed Security Service Providers (MSSPs) to deliver unparalleled cybersecurity outcomes through a comprehensive and expanded suite of services designed to stay ahead of the rapidly evolving threat landscape. The acquisition will create the largest pure-play MSSP in the industry. The acquisition will integrate LevelBlue’s extensive expertise in strategic risk management and cybersecu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom